171 related articles for article (PubMed ID: 34463926)
1. Curcumin Sensitizes Prolactinoma Cells to Bromocriptine by Activating the ERK/EGR1 and Inhibiting the AKT/GSK-3β Signaling Pathway In Vitro and In Vivo.
Tang C; Zhu J; Yuan F; Yang J; Cai X; Ma C
Mol Neurobiol; 2021 Dec; 58(12):6170-6185. PubMed ID: 34463926
[TBL] [Abstract][Full Text] [Related]
2. Bromocriptine and cabergoline induce cell death in prolactinoma cells via the ERK/EGR1 and AKT/mTOR pathway respectively.
Tang C; Sun R; Wen G; Zhong C; Yang J; Zhu J; Cong Z; Luo X; Ma C
Cell Death Dis; 2019 Apr; 10(5):335. PubMed ID: 31000722
[TBL] [Abstract][Full Text] [Related]
3. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas.
Wang S; Wang A; Zhang Y; Zhu K; Wang X; Chen Y; Wu J
BMC Endocr Disord; 2021 Nov; 21(1):235. PubMed ID: 34814904
[TBL] [Abstract][Full Text] [Related]
4. Tumor suppressor miR-145-5p sensitizes prolactinoma to bromocriptine by downregulating TPT1.
Jian M; Du Q; Zhu D; Mao Z; Wang X; Feng Y; Xiao Z; Wang H; Zhu Y
J Endocrinol Invest; 2019 Jun; 42(6):639-652. PubMed ID: 30370446
[TBL] [Abstract][Full Text] [Related]
5. Bromocriptine Induces Autophagy-Dependent Cell Death in Pituitary Adenomas.
Geng X; Ma L; Li Z; Li Z; Li J; Li M; Wang Q; Chen Z; Sun Q
World Neurosurg; 2017 Apr; 100():407-416. PubMed ID: 28137551
[TBL] [Abstract][Full Text] [Related]
6. Curcumin (diferuloylmethane) inhibits cell proliferation, induces apoptosis, and decreases hormone levels and secretion in pituitary tumor cells.
Miller M; Chen S; Woodliff J; Kansra S
Endocrinology; 2008 Aug; 149(8):4158-67. PubMed ID: 18450960
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of SKP2 Sensitizes Bromocriptine-Induced Apoptosis in Human Prolactinoma Cells.
Huang J; Zhang F; Jiang L; Hu G; Sun W; Zhang C; Ding X
Cancer Res Treat; 2017 Apr; 49(2):358-373. PubMed ID: 27488872
[TBL] [Abstract][Full Text] [Related]
8. PGAM5-CypD pathway is involved in bromocriptine-induced RIP3/MLKL-dependent necroptosis of prolactinoma cells.
Zhang SL; Tang HB; Hu JT; Zang ZL; Ding X; Li S; Yang H
Biomed Pharmacother; 2019 Mar; 111():638-648. PubMed ID: 30611988
[TBL] [Abstract][Full Text] [Related]
9. Pimozide augments bromocriptine lethality in prolactinoma cells and in a xenograft model via the STAT5/cyclin D1 and STAT5/Bcl‑xL signaling pathways.
Xiao Z; Liang J; Deng Q; Song C; Yang X; Liu Z; Shao Z; Zhang K; Wang X; Li Z
Int J Mol Med; 2021 Jan; 47(1):113-124. PubMed ID: 33155660
[TBL] [Abstract][Full Text] [Related]
10. Curcumin affects autophagy of prolactinoma cells by upregulating miR-206 to exert antitumor effects.
Duan JF; Zhang QJ; Zhu J; Lu JH
J Biochem Mol Toxicol; 2024 Jun; 38(6):e23734. PubMed ID: 38764151
[TBL] [Abstract][Full Text] [Related]
11. ACT001 reverses resistance of prolactinomas via AMPK-mediated EGR1 and mTOR pathways.
Zhu J; Tang C; Cong Z; Yuan F; Cai X; Yang J; Ma C
Endocr Relat Cancer; 2021 Dec; 29(2):33-46. PubMed ID: 34821219
[TBL] [Abstract][Full Text] [Related]
12. Curcumin and Nano-Curcumin Mitigate Copper Neurotoxicity by Modulating Oxidative Stress, Inflammation, and Akt/GSK-3β Signaling.
Sarawi WS; Alhusaini AM; Fadda LM; Alomar HA; Albaker AB; Aljrboa AS; Alotaibi AM; Hasan IH; Mahmoud AM
Molecules; 2021 Sep; 26(18):. PubMed ID: 34577062
[TBL] [Abstract][Full Text] [Related]
13. Combined treatment with artesunate and bromocriptine has synergistic anticancer effects in pituitary adenoma cell lines.
Wang X; Du Q; Mao Z; Fan X; Hu B; Wang Z; Chen Z; Jiang X; Wang Z; Lei N; Wang H; Zhu Y
Oncotarget; 2017 Jul; 8(28):45874-45887. PubMed ID: 28501857
[TBL] [Abstract][Full Text] [Related]
14. Curcumin Ameliorates Lead-Induced Hepatotoxicity by Suppressing Oxidative Stress and Inflammation, and Modulating Akt/GSK-3β Signaling Pathway.
Alhusaini A; Fadda L; Hasan IH; Zakaria E; Alenazi AM; Mahmoud AM
Biomolecules; 2019 Nov; 9(11):. PubMed ID: 31694300
[TBL] [Abstract][Full Text] [Related]
15. Dopamine receptor D2S gene transfer improves the sensitivity of GH3 rat pituitary adenoma cells to bromocriptine.
Li Q; Su Z; Liu J; Cai L; Lu J; Lin S; Xiong Z; Li W; Zheng W; Wu J; Zhuge Q; Wu Z
Mol Cell Endocrinol; 2014 Jan; 382(1):377-384. PubMed ID: 24184771
[TBL] [Abstract][Full Text] [Related]
16. The role of TGF-β/Smad signaling in dopamine agonist-resistant prolactinomas.
Li Z; Liu Q; Li C; Zong X; Bai J; Wu Y; Lan X; Yu G; Zhang Y
Mol Cell Endocrinol; 2015 Feb; 402():64-71. PubMed ID: 25578603
[TBL] [Abstract][Full Text] [Related]
17. Resveratrol inhibited GH3 cell growth and decreased prolactin level via estrogen receptors.
Wang C; Hu ZQ; Chu M; Wang Z; Zhang WG; Wang LZ; Li CG; Wang JS
Clin Neurol Neurosurg; 2012 Apr; 114(3):241-8. PubMed ID: 22104698
[TBL] [Abstract][Full Text] [Related]
18. Letrozole Decreased Testosterone-Induced Cell Proliferation and Prolactin Secretion also Increased Apoptosis in MMQ and GH3 Rat Prolactinoma Cell Lines.
Selek A; Halbutoğulları ZSU; Aydemir Çİ; Cetinarslan B; Canturk Z; Tarkun I; Erman G; Subaşı C; Erdal K
Mol Neurobiol; 2023 May; 60(5):2442-2454. PubMed ID: 36662360
[TBL] [Abstract][Full Text] [Related]
19. Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas.
Caccavelli L; Morange-Ramos I; Kordon C; Jaquet P; Enjalbert A
J Neuroendocrinol; 1996 Oct; 8(10):737-46. PubMed ID: 8910802
[TBL] [Abstract][Full Text] [Related]
20. miR-93-5p targets Smad7 to regulate the transforming growth factor-β1/Smad3 pathway and mediate fibrosis in drug-resistant prolactinoma.
Hu B; Mao Z; Du Q; Jiang X; Wang Z; Xiao Z; Zhu D; Wang X; Zhu Y; Wang H
Brain Res Bull; 2019 Jul; 149():21-31. PubMed ID: 30946881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
